@article{JTD20364,
author = {Feliciano Barrón and Andrés F. Cardona and Luis Corrales and Laura-Alejandra Ramirez-Tirado and Enrique Caballe-Perez and Gisela Sanchez and Diana Flores-Estrada and Zyanya Lucia Zatarain-Barrón and Oscar Arrieta and on behalf of Latin American Consortium for the Study of Lung Cancer (CLICaP)},
title = {Characteristics of progression to tyrosine kinase inhibitors predict overall survival in patients with advanced non-small cell lung cancer harboring an EGFR mutation},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {4},
year = {2018},
keywords = {},
abstract = {Background: Non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations has a distinct biology and heterogeneous clinical behavior. We evaluated the characteristics to progression such as clinical patterns of progression (dramatic, gradual, and local) with the prognosis of NSCLC patients treated with tyrosine kinase inhibitors (TKIs).
Methods: We reviewed 123 advanced-NSCLC patients with an EGFR-sensitizing mutation treated with TKIs (gefitinib, erlotinib and afatinib). We assessed patients according to clinical factors and progression pattern to TKIs at three centers.
Results: For all patients, 58.5%, 31.7% and 9.8% harbored exon19 deletion, exon21 L858R mutation and other-sensitivity mutations, respectively. Median progression-free survival (PFS) was 8.8 months (95% CI: 7.9–9.7). Sixty percent of patients were asymptomatic. Dramatic-progression was the most frequent pattern (50.4%), followed by gradual-progression (32.5%), and local-progression (17.1%). Median overall survival (OS) was 23.1 months (95% CI: 17.4–28.9). In the univariate analysis, factors associated to a longer OS included pattern [gradual-progression (32.1), dramatic (19.5) and local (18.8 months), P=0.008], and the time to progression to TKI [>12 months (38.5), 6-12 months (19.1), },
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/20364}
}